Skip to main content

Millipore Expands Drug Discovery Facilities in Missouri

NEW YORK (GenomeWeb News) – Millipore said today that it will spend $3.4 million to expand its drug discovery business unit’s operations in St. Charles, Mo.
 
The Billerica, Mass.-based firm also said that it plans to hire an additional 60 employees at the St. Charles site. Millipore gained the site through its $1.4 billion acquisition of Serologicals in 2006.
 
The firm said that it is seeking LEED certification of the expanded and renovated 17,000-square-foot space. Millipore noted that the expanded facility is one of three buildings on the firm’s 43-acre Missouri Research Park campus.
 
“Our expanded St. Charles facility will help us meet the needs of customers at every stage of the drug discovery and development pipeline — from target identification through clinical studies,” Rick Ryan, vice president of Millipore’s drug discovery and development business unit, said in a statement.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.